N/A N=51 Cardiovascular Complications of Sickle Cell Disease
Sickle Cell Disease
Primary: MRI Parameter - LVEDVi, mL/cm2 (Measured Using Method of Disks, Controls Serve as Normal Ranges) — 124.0; 78.7 mL/cm2 — p=0.0039
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=65 Singing and Cardiovascular Health in Older Adults
Cardiovascular Diseases · Cardiovascular Risk Factor · Cardiovascular Health
Primary: Change in FMD% — -0.06; -0.11; -0.06 FMD percent — p=0.864
N/A N=428 Cardiovascular Intervention Improvement Telemedicine Study
Cardiovascular Disease · Hypertension · Diabetes
Primary: Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent) — 32.4; 31.6 % 10 yr Risk
Phase 4 N=76 Cardiovascular Function in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment — 2.855; 2.317 Millilitre/ meter^2 (mL/m^2) — p=0.6331
N/A N=66 Study of the Long-term Effects of Exercise on Heath Indicators in Older People
Hypertension With Complications and Secondary Hypertension · Overweight and Obesity · Lipid Metabolism Disorders
Primary: Cardiovascular Disease Risk Factors — 3; 4; 5; 7 participants
N/A N=657 Measuring Cardiovascular Performance and Blood Flow Using Common But Never Compared Methods.
D012039 · D001775
Primary: Feasibility of Performing Echo, BNP, and VP on Human Subjects. — 657; 236 Participants
N/A N=2,039 Pathways to Cardiovascular Disease Prevention (DCRI Central and Statistical Coordinating Center)
HIV/AIDS · Cardiovascular Diseases
Primary: Number of Participants With Visit to a Cardiology Specialist From Cohort — 283 Participants
N/A N=51 PCI Alternative Using Sustained Exercise
Cardiovascular Disease
Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio
N/A N=69 The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults
Cardiovascular Diseases · Cardiovascular Abnormalities · Heart Attack
Primary: Change From Baseline of Total Cholesterol After 90 Days — -0.57; -1.09 mmol/L — p=0.042
N/A N=20 Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults
Prediabetes · Cardiovascular Disease
Primary: Vascular Endothelial Function — -294.4; -152.9; -102.9; -361.6 %FMD*min
N/A N=6,009 Cardiovascular Risk Screening and Risk Reduction in Women Vets
Cardiovascular Diseases · Hypertension · Hyperlipidemias
Primary: New Participation in MOVE! (Among Women Aged 65 and Older) — 1.09 Odds Ratio — p=.003
N/A N=19 Heart at Work Study
Occupational Diseases · Cardiovascular Diseases · Cardiovascular Risk Factor
Primary: 24-hour Heart Rate — 83.8; 78.5 beats per minute
N/A N=202 Impact of a Corrie Cardiac Rehabilitation Program
Coronary Artery Disease · Myocardial Infarction · Myocardial Ischemia
Primary: 6-minute Walking Distance (Meters) — 506.1; 489.8 meters — p=0.04
N/A N=118 Prevention of Cardiovascular Disease With Med or Veg Diets
Cardiovascular Disease
Primary: Changes in Body Weight From Baseline — -1.88; -1.77 Kilograms
Phase 4 N=93 Cardiovascular Effects of GLP-1 Receptor Activation
Obesity · PreDiabetes
Primary: Change in Flow-mediated Dilation — 0.71; 2.06; 1.24; 0.48 Percentage
N/A N=21,664 Pre-Diabetes Cardiovascular (CV) Care (Pre-Diabetes Wizard)
Pre-diabetes
Primary: Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke — 1.100; 1.096 units on a scale — p=<0.05
Phase 4 N=87 Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
Cardiovascular Diseases · Hepatitis C · Hiv
Primary: Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein — 0.6; 0 mg/L
N/A N=104,219 Cardiovascular Disease Population Risk Tool
Cardiovascular Diseases
Primary: Major Cardiovascular Disease Event — 3182; 527 Cardiovascular disease event
N/A N=77 Complement and Cardiovascular Risk in Adolescents
Cardiovascular Disease · Type 2 Diabetes
Primary: Complement C3 Genotype — 22; 45; 2; 6 Participants
N/A N=68 Hybrid-FES Exercise to Prevent Cardiovascular Declines in Acute SCI
Spinal Cord Injury
Primary: Change From Baseline in Exercise Capacity at 6 Months — 14.6; 18.5; 17.1; 13.9 ml/kg/min
N/A N=41 Cardiovascular Responses to Heat Waves in the Elderly
Aging · Hyperthermia
Primary: Change in Core Body Temperature — .68; 1.37; .58; 1.02 degrees Celsius (°C)
N/A N=10,347 Reducing Cardiovascular Risk in Adults With Serious Mental Illness
Chronic Disease · Mental Disorder · Health Behavior
Primary: Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke — 14.2; 20.8 percentage of annual rate of change
N/A N=20 Vascular Endothelium Changes After Bariatric Surgery (Endothelial Progenitor Cells)
Type 2 Diabetes
Primary: Change in Late Outgrowth Endothelial Progenitor Colonies — 0.3; 0.2; 3.1; 0.1 LOEPC colonies — p=<0.05
N/A N=17 Comprehensive Cardiac Rehabilitation Feasibility After Stroke
Stroke, Ischemic
Primary: Attendance Rate — 8 Participants
N/A N=10 Transcutaneous Stimulation in Spinal Cord Injury
Spinal Cord Injury
Primary: Seated Systolic Blood Pressure — 86; 100.4; 102.7; 101.3 mmHg
Phase 3 N=25 The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients
Abdominal Obesity · Hypertension
Primary: Change in Reactive Hyperemic Index by Period (Carvedilol CR + Lisinopril vs. Lisinopril + HCTZ) — -0.26; -0.14 Ratio
N/A N=434 VAscular Closure for Cardiac Ablation Registry (VACCAR)
Atrial Fibrillation
Primary: Hemostasis — 9; 20; 7 minutes
N/A N=13,381 Prioritized Clinical Decision Support (CDS) to Reduce Cardiovascular Risk
Hypertension · Hyperlipidemia · Diabetes
Primary: Predicted Annual Rate of Change in 10-year Risk of Fatal or Nonfatal Heart Attack or Stroke — -0.59; 1.66 annualized change in 10 year % cv risk — p=<0.05
Phase 3 N=26 24 Hour Ambulatory Cardiac Oxygen Consumption
Hypertension
Primary: ACRPP: 24-hour Ambulatory Central Rate-pressure Product (Also Called TTI, CTTI) — 2531; 2824; 2484 mmHg*beats/min — p=0.05
N/A N=70 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
Impaired Glucose Tolerance · Prediabetic State
Primary: AIM 1: Change in Flow Mediated Dilation (FMD) (%) — -0.0012; 0.018; 0.014; 0.0053 percentage of arterial dilation change — p=0.943